Floatz logo

Gdc-0449

Adult Synovial Sarcoma

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Adult Synovial Sarcoma cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Cyclophosphamide
Zelluna Immunotherapy AS
Phase 2BB
Pembrolizumab
Valo Therapeutics Oy
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B

View all 36 →

Same molecule, other indications

Gdc-0449 is also rated in:

exocrine pancreatic carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
adult glioblastomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →